Registry-only phase 2 and 3 trials that name pancreatic cancer in their title or conditions, recorded from ClinicalTrials.gov during the pancreatic cancer deep dive of September 2026; registry facts only, no outcomes. 284 records carry it: 284 trials.
A phase 2 trial of gemcitabine + nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.
A phase 2 trial of SSGJ-706, cAPOX (capecitabine, oxaliplatin) and bevacizumab in pancreatic cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., not yet recruiting.
A phase 2 trial of navlimetostat, gemcitabine, nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by M.D. Anderson Cancer Center, now recruiting.
A phase 1/2 trial of cetuximab, nab-paclitaxel, gemcitabine, fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.
A phase 3 trial of YL201, liposomal irinotecan, fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., not yet recruiting.
A phase 2 trial of adebrelimab, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Jiang Long, now recruiting.
A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.
A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.
A phase 2 trial of gemcitabine + nab-paclitaxel and nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.
A phase 2 trial of cisplatin, nab-paclitaxel, capecitabine and gemcitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
A phase 1/2 trial of gemcitabine, nab-paclitaxel, erlotinib, nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) and other drugs in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.